{"id":50836,"date":"2025-12-15T21:00:48","date_gmt":"2025-12-15T13:00:48","guid":{"rendered":"https:\/\/flcube.com\/?p=50836"},"modified":"2025-12-15T21:00:49","modified_gmt":"2025-12-15T13:00:49","slug":"junshi-biosciences-wins-fda-nod-for-egfr-her3-bispecific-adc-in-solid-tumors","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=50836","title":{"rendered":"Junshi Biosciences Wins FDA Nod for EGFR\/HER3 Bispecific ADC in Solid Tumors"},"content":{"rendered":"\n<p><strong>Shanghai Junshi Biosciences Co., Ltd.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/1877:HKG\">HKG: 1877<\/a>, <a href=\"https:\/\/www.google.com\/finance\/quote\/688180:SHA\">SHA: 688180<\/a>) announced that the U.S. <strong>Food and Drug Administration (FDA)<\/strong> cleared an Investigational New Drug (IND) application for <strong>JS212<\/strong>, a recombinant humanized <strong>anti\u2011EGFR\/HER3 bispecific antibody\u2011drug conjugate (ADC)<\/strong>, for the treatment of <strong>advanced solid tumors<\/strong>. The drug previously received NMPA approval for clinical trials in China in March\u202f2025.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-drug-profile-amp-mechanism\">Drug Profile &amp; Mechanism<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>JS212<\/th><th>Competitive Context<\/th><\/tr><\/thead><tbody><tr><td><strong>Targets<\/strong><\/td><td>EGFR and HER3 (bispecific)<\/td><td>Single\u2011target ADCs limited by resistance<\/td><\/tr><tr><td><strong>Mechanism<\/strong><\/td><td>ADC binding to either EGFR or HER3 \u2192 tumor inhibition<\/td><td>Broader tumor coverage vs. monospecific agents<\/td><\/tr><tr><td><strong>Preclinical Data<\/strong><\/td><td>High\u2011affinity, specific binding; significant tumor inhibition across multiple models<\/td><td>Demonstrates activity in EGFR\/HER3 co\u2011expressing tumors<\/td><\/tr><tr><td><strong>Safety<\/strong><\/td><td>Favorable and acceptable safety profile<\/td><td>Differentiated toxicity vs. EGFR\u2011only inhibitors<\/td><\/tr><tr><td><strong>Innovation<\/strong><\/td><td>First China\u2011developed EGFR\/HER3 bispecific ADC cleared by FDA<\/td><td>Positions Junshi in next\u2011generation ADC wave<\/td><\/tr><tr><td><strong>Clinical Stage<\/strong><\/td><td>Phase\u202f1 ready in US; China trial ongoing<\/td><td>Global development strategy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-amp-development-strategy\">Market Opportunity &amp; Development Strategy<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Indication:<\/strong> Advanced solid tumors (potentially lung, breast, colorectal cancers with EGFR\/HER3 expression)<\/li>\n\n\n\n<li><strong>Global ADC Market:<\/strong> $13\u202fbillion (2025), projected $30\u202fbillion by 2030; bispecific ADCs represent <strong>highest growth subsegment<\/strong><\/li>\n\n\n\n<li><strong>Resistance Mechanism:<\/strong> Dual targeting aims to overcome <strong>primary and acquired resistance<\/strong> to EGFR\u2011targeted therapies (e.g., osimertinib)<\/li>\n\n\n\n<li><strong>Regulatory Path:<\/strong> FDA IND clearance enables <strong>Phase\u202f1 US trial initiation in Q1\u202f2026<\/strong>; China data may support global registration<\/li>\n\n\n\n<li><strong>Peak Sales Potential:<\/strong> <strong>\u00a52\u20113\u202fbillion<\/strong> (\u2248\u202fUS$280\u2011420\u202fM) globally by 2033 if approved in 2\u20113 tumor types<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>For Junshi:<\/strong> <strong>Bispecific ADC platform<\/strong> validated by dual regulatory approvals (China and US); JS212 complements its <strong>PD\u20111 franchise<\/strong> (toripalimab) in solid tumors; potential for <strong>global partnerships<\/strong> if early clinical data is positive.<\/li>\n\n\n\n<li><strong>For ADC Field:<\/strong> <strong>EGFR\/HER3 bispecific design<\/strong> addresses resistance to first\u2011gen EGFR ADCs (e.g., Enhertu); positions Junshi alongside <strong>AstraZeneca\/Daiichi Sankyo<\/strong> and <strong>GSK<\/strong> in next\u2011wave ADC competition.<\/li>\n\n\n\n<li><strong>For Patients:<\/strong> Offers <strong>new therapeutic option<\/strong> for EGFR\u2011mutated\/HER3\u2011positive tumors post\u2011progression; bispecificity may enhance <strong>tumor selectivity<\/strong> and reduce off\u2011target toxicity.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding JS212\u2019s clinical development timeline, market size estimates, and competitive positioning. Actual results may differ due to regulatory delays, clinical risks, or competitive responses.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced that the U.S. Food and&#8230;<\/p>\n","protected":false},"author":1,"featured_media":50837,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[35,62,899,28,900],"class_list":["post-50836","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-adc-xdc","tag-clinical-trial-approval-initiation","tag-hkg-1877","tag-multi-specific-antibodies","tag-sha-688180"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Junshi Biosciences Wins FDA Nod for EGFR\/HER3 Bispecific ADC in Solid Tumors - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced that the U.S. Food and Drug Administration (FDA) cleared an Investigational New Drug (IND) application for JS212, a recombinant humanized anti\u2011EGFR\/HER3 bispecific antibody\u2011drug conjugate (ADC), for the treatment of advanced solid tumors. The drug previously received NMPA approval for clinical trials in China in March\u202f2025.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=50836\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Junshi Biosciences Wins FDA Nod for EGFR\/HER3 Bispecific ADC in Solid Tumors\" \/>\n<meta property=\"og:description\" content=\"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced that the U.S. Food and Drug Administration (FDA) cleared an Investigational New Drug (IND) application for JS212, a recombinant humanized anti\u2011EGFR\/HER3 bispecific antibody\u2011drug conjugate (ADC), for the treatment of advanced solid tumors. The drug previously received NMPA approval for clinical trials in China in March\u202f2025.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=50836\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-12-15T13:00:48+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-12-15T13:00:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1506.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50836#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50836\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Junshi Biosciences Wins FDA Nod for EGFR\\\/HER3 Bispecific ADC in Solid Tumors\",\"datePublished\":\"2025-12-15T13:00:48+00:00\",\"dateModified\":\"2025-12-15T13:00:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50836\"},\"wordCount\":373,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50836#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1506.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Clinical trial approval \\\/ initiation\",\"HKG: 1877\",\"Multi-specific antibodies\",\"SHA: 688180\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50836#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50836\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=50836\",\"name\":\"Junshi Biosciences Wins FDA Nod for EGFR\\\/HER3 Bispecific ADC in Solid Tumors - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50836#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50836#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1506.webp\",\"datePublished\":\"2025-12-15T13:00:48+00:00\",\"dateModified\":\"2025-12-15T13:00:49+00:00\",\"description\":\"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced that the U.S. Food and Drug Administration (FDA) cleared an Investigational New Drug (IND) application for JS212, a recombinant humanized anti\u2011EGFR\\\/HER3 bispecific antibody\u2011drug conjugate (ADC), for the treatment of advanced solid tumors. The drug previously received NMPA approval for clinical trials in China in March\u202f2025.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50836#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=50836\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50836#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1506.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/12\\\/1506.webp\",\"width\":1080,\"height\":608,\"caption\":\"Junshi Biosciences Wins FDA Nod for EGFR\\\/HER3 Bispecific ADC in Solid Tumors\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=50836#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Junshi Biosciences Wins FDA Nod for EGFR\\\/HER3 Bispecific ADC in Solid Tumors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Junshi Biosciences Wins FDA Nod for EGFR\/HER3 Bispecific ADC in Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","description":"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced that the U.S. Food and Drug Administration (FDA) cleared an Investigational New Drug (IND) application for JS212, a recombinant humanized anti\u2011EGFR\/HER3 bispecific antibody\u2011drug conjugate (ADC), for the treatment of advanced solid tumors. The drug previously received NMPA approval for clinical trials in China in March\u202f2025.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=50836","og_locale":"en_US","og_type":"article","og_title":"Junshi Biosciences Wins FDA Nod for EGFR\/HER3 Bispecific ADC in Solid Tumors","og_description":"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced that the U.S. Food and Drug Administration (FDA) cleared an Investigational New Drug (IND) application for JS212, a recombinant humanized anti\u2011EGFR\/HER3 bispecific antibody\u2011drug conjugate (ADC), for the treatment of advanced solid tumors. The drug previously received NMPA approval for clinical trials in China in March\u202f2025.","og_url":"https:\/\/flcube.com\/?p=50836","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-12-15T13:00:48+00:00","article_modified_time":"2025-12-15T13:00:49+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1506.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=50836#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=50836"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Junshi Biosciences Wins FDA Nod for EGFR\/HER3 Bispecific ADC in Solid Tumors","datePublished":"2025-12-15T13:00:48+00:00","dateModified":"2025-12-15T13:00:49+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=50836"},"wordCount":373,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=50836#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1506.webp","keywords":["ADC \/ XDC","Clinical trial approval \/ initiation","HKG: 1877","Multi-specific antibodies","SHA: 688180"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=50836#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=50836","url":"https:\/\/flcube.com\/?p=50836","name":"Junshi Biosciences Wins FDA Nod for EGFR\/HER3 Bispecific ADC in Solid Tumors - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=50836#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=50836#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1506.webp","datePublished":"2025-12-15T13:00:48+00:00","dateModified":"2025-12-15T13:00:49+00:00","description":"Shanghai Junshi Biosciences Co., Ltd. (HKG: 1877, SHA: 688180) announced that the U.S. Food and Drug Administration (FDA) cleared an Investigational New Drug (IND) application for JS212, a recombinant humanized anti\u2011EGFR\/HER3 bispecific antibody\u2011drug conjugate (ADC), for the treatment of advanced solid tumors. The drug previously received NMPA approval for clinical trials in China in March\u202f2025.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=50836#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=50836"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=50836#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1506.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1506.webp","width":1080,"height":608,"caption":"Junshi Biosciences Wins FDA Nod for EGFR\/HER3 Bispecific ADC in Solid Tumors"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=50836#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Junshi Biosciences Wins FDA Nod for EGFR\/HER3 Bispecific ADC in Solid Tumors"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/12\/1506.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50836","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=50836"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50836\/revisions"}],"predecessor-version":[{"id":50838,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/50836\/revisions\/50838"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/50837"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=50836"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=50836"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=50836"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}